Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Tepezza® (teprotumumab-trbw) – Updated indication
April 14, 2023 - Horizon Therapeutics announced the FDA approval of Tepezza (teprotumumab-trbw), for the treatment of thyroid eye disease regardless of thyroid eye disease activity or duration.
